Analysis by alkylating agents, mitotic inhibitors, antirheumatic agents, antipsoriatic agents, VEGF/VEGFR inhibitors, PARP inhibitors and antineoplastic agents

DUBLIN, January 23, 2023 /PRNewswire/ — The report Ovarian Cancer Drugs Market – Global Industry Size, Share, Trends, Opportunities and Forecast, 2017-2027, Segmented by Drug Class, by Tumor Type, by Distribution Channel, by Region ‘ has been added to supply.

Research and Markets Logo

The global ovarian cancer drug market is expected to witness an impressive growth during the forecast period 2023-2027.

Ovarian cancer is one of the most serious and common cancers affecting women today. The ovaries in this malignancy undergo abnormal cell proliferation that can invade or negatively affect other parts of the body such as the liver, lymph nodes, bowel and bladder lining, abdominal layers and lymph nodes.

The early stages of ovarian cancer are accompanied by several vague symptoms that become more apparent as the malignancy progresses. These signs include bloating, pelvic pain, bloating and loss of appetite. The risk of ovarian cancer is higher in women who have had more frequent ovulation throughout their lives, which can include women who have never given birth and those who started ovulating at a young age.

The American Cancer Society estimates that inherited genetic factors contribute to about 10% of ovarian cancer cases. 50% of women who carry BRCA1 or BRCA2 gene mutations will develop breast or ovarian cancer. The most common type of ovarian cancer, accounting for 95% of cases worldwide, is ovarian carcinoma.

Increasing prevalence of ovarian cancer

Ovarian cancer drug market is growing in an extremely favorable environment due to the recent increase in ovarian cancer cases. The American Cancer Society reports that in 2016, there were approximately 22,280 newly diagnosed cases of ovarian cancer, resulting in 14,240 deaths in United States.

Ovarian cancer accounted for 1.3% of the incidence rate and 2.4% of all cancer deaths in 2016, according to statistics from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program .

In 2020, there will be 23,820 new cases of ovarian cancer, and the American Cancer Society estimates that 1 in 75 women will develop ovarian cancer in their lifetime, with a 1 in 100 risk that she will die from it.

As of 2017, 1,580 new cases of ovarian cancer are expected to be diagnosed, making up about 2.5% of all new cancer cases in the nation, according to the Australian government’s Cancer Australia. 1047 deaths are expected due to this in 2017.

Hence, the ovarian cancer drug sector is expected to experience significant growth in developed countries soon.

Increase in the elderly female population

Increasing percentage of elderly female population is expected to drive the global ovarian cancer drug market during the forecast period.

As the population of elderly women increases, they are expected to suffer from more gynecological problems. For example, according to World Population Prospects, by 2021, there were about 9.5% women above the age group of 60 years, of which the majority of the female population is susceptible to gynecological infections or diseases or cancer.

The prevalence of ovarian cancer is often low in women under the age of 40. Most cases of ovarian cancer occur in women age 60 and older, according to the American Cancer Society. 7,378 new cases of ovarian cancer were reported in the nation in 2014, with approximately 53% of these cases identified in women aged 65 and over, according to Cancer Research UK.

Increasing research and development to develop drugs for ovarian cancer

The increasing prevalence of ovarian cancer has prompted companies operating in the market along with various research organizations to increase their research and development activities to develop potential drug treatment for ovarian cancer. Companies in the pharmaceutical business are increasingly coming up with new drug combinations to treat ovarian cancer.

To treat complex medical conditions, combination drugs combine two or more active pharmaceutical ingredients (APIs) in a single dosage form. To reduce manufacturing costs, increase compliance and effectiveness, improve drug compliance, increase profitability, and reduce side effects, pharmaceutical companies in the ovarian cancer drug market are investing in the research and development of new products such as combination drugs.

For example, Roche’s well-known tranquilizer Avastin (bevacizumab), which is used to treat advanced stage (III or IV) ovarian cancer, is an FDA-approved combination drug that contains ingredients such as carboplatin and paclitaxel.

Regionally, North America dominated the market among Europe, Asia and the Pacific, Middle East and Africa and South America. United States held the largest market in North America region and is expected to be a lucrative market during the forecast period as the government invests in research for new drugs to easily detect ovarian cancer in the affected people.

The competitive environment

Company Profiles: Detailed analysis of major companies present in the global ovarian cancer drug market.

Report Scope:

In this report, the global Ovarian Cancer Drugs market is segmented into the following categories in addition to the industry trends, which are also detailed below:

Ovarian Cancer Drug Market, by Drug Class:

  • Alkylating agents

  • Mitotic inhibitors

  • Antirheumatic drugs

  • Antipsoriatic agents

  • VEGF/VEGFR inhibitors

  • PARP inhibitors

  • Antineoplastic agents

  • others

Ovarian Cancer Drug Market, by Tumor Type:

Ovarian Cancer Drugs Market, by Distribution Channel:

  • Hospital pharmacies

  • Retail pharmacies

  • Online pharmacies

Ovarian Cancer Drug Market, by Region:

  • North America

  • United States

  • Canada

  • Mexico

  • Europe

  • Germany

  • France

  • Great Britain

  • Spain

  • Italy

  • Asia and the Pacific

  • China

  • India

  • Japan

  • South Korea

  • Australia

  • South America

  • Brazil

  • Argentina

  • Colombia

  • Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

For more information on this report, visit

About is the world’s leading source for international market research reports and market data. We bring you the latest data on international and regional markets, key industries, leading companies, new products and the latest trends.

Media contact:

Research and Markets
Laura WoodSenior Manager
[email protected]




See original content: vegfvegfr-inhibitors-parp-inhibitors–antineoplastics-301727440.html

SOURCE Research and Markets

Leave a Comment

Your email address will not be published. Required fields are marked *